Dried Tetraselmis chuii powder,
does it really help with Improvement of dry eye and tear secretion?
research showsIn 2025, the Korean Ministry of Food and Drug Safety individually recognized this exact ingredient at 480 mg/day, which means a human study was included in the review. However, public searches did not disclose the sample size, endpoints, numerical findings, or a peer-reviewed human paper, while published literature is mainly animal dry-eye research, so the grade is low C.
ads claimAdvertising may translate regulatory recognition and animal mechanisms directly into human tear-production effects. Public data do not allow assessment of effect size, symptom improvement, failed endpoints, or independent reproducibility.
Useful facts when choosing a product
- The recognized daily intake is 480 mg/day.
- The ingredient holder is Milae Bioresources and the recognition number is 2025-48.
- Overseas TetraSOD products of the same species differ in strain, dose, and standardization and are not directly interchangeable evidence.
- The Korean safety information advises avoidance by children and during pregnancy or lactation and caution in people with allergic constitutions.
What the research actually shows
The Korean food-safety portal identifies Milae Bioresources dried Tetraselmis chuii powder, recognition number 2025-48, for relief of dry eyes at 480 mg/day. A human application study was submitted through the individual-recognition process, but its detailed design and results were not available on the public page. The 2023 study by Kim and colleagues and the 2025 study by Hong and colleagues reported improvements in tear volume, corneal measures, and inflammation in dry-eye mouse models using the same microalgal species.
Why this is classified as C (42)
Regulatory recognition itself is not grading evidence, but the dossier confirms a human study of the exact ingredient, so the grade is not unknown. Positive evidence is limited to one manufacturer-specific proprietary product, the full results, sample size, and major endpoints are not public, and no independent replication exists, supporting C with 42 points.
Counterpoint. The exact 480 mg/day ingredient has human data submitted for review. The current score reflects limited public verifiability.
Rejudgment record. Reassessment (cross-check reflected) — Regulatory recognition is not grading evidence, but it confirms a human study of the exact manufacturer-specific product; sample size, endpoints, and numerical results are not public, no independent replication exists, and published literature is mainly preclinical
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| MFDS recognition dossier 2025-48 | Human application study submitted for individual-recognition review; details not public | Associated with ingredient applicant Milae Bioresources | Improvement of dry eyes | Recognition is confirmed, but numerical results and major endpoints were not available in the public record. | Key | |
| Kim JW et al. 2023 | Scopolamine dry-eye mouse study | Coauthors affiliated with KIST and Milae Bioresources | Tear volume, cornea, lacrimal gland, and inflammation | T. chuii improved tear volume and tissue and inflammatory measures. | Supportive |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-11).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none
Cite this verdict
[Chamgap] Dried Tetraselmis chuii powder × Improvement of dry eye and tear secretion — Evidence Grade C·42. 2 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/eye/tetraselmis-chuii-dry-eye/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.